Abstract
Chronic ischemic heart disease remains a major cause of morbidity and mortality worldwide. Although revascularisation strategies and pharmaceutical therapy are able to delay ventricular remodelling, until today no therapeutic strategy is available that might prevent or even reverse this process of remodelling and consequent ventricular failure. In the recent past, experimental and clinical studies have demonstrated the capacity of bone marrow stem cells in cardiac repair and regeneration of compromised heart muscle. Several clinical trials showed the safety and efficacy of autologous bone marrow stem cell transplantation in the patients with acute myocardial infarction or chronic ischemic heart disease. Today the therapeutic strategy of cell administration during cardiac surgery or coronary artery intervention is entering the clinical practice. In the following Review we will highlight biological as well as methodological backgrounds, indications and clinical results of cardiac stem cell therapy for the treatment of acute myocardial infarction and chronic ischemic heart disease.
Keywords: Bone marrow, ischemic heart disease, myocardial infarction, stem cells, transplantation, trial
Current Pharmaceutical Biotechnology
Title:Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Volume: 14 Issue: 1
Author(s): Peter Donndorf, Bodo-Eckhard Strauer, Axel Haverich and Gustav Steinhoff
Affiliation:
Keywords: Bone marrow, ischemic heart disease, myocardial infarction, stem cells, transplantation, trial
Abstract: Chronic ischemic heart disease remains a major cause of morbidity and mortality worldwide. Although revascularisation strategies and pharmaceutical therapy are able to delay ventricular remodelling, until today no therapeutic strategy is available that might prevent or even reverse this process of remodelling and consequent ventricular failure. In the recent past, experimental and clinical studies have demonstrated the capacity of bone marrow stem cells in cardiac repair and regeneration of compromised heart muscle. Several clinical trials showed the safety and efficacy of autologous bone marrow stem cell transplantation in the patients with acute myocardial infarction or chronic ischemic heart disease. Today the therapeutic strategy of cell administration during cardiac surgery or coronary artery intervention is entering the clinical practice. In the following Review we will highlight biological as well as methodological backgrounds, indications and clinical results of cardiac stem cell therapy for the treatment of acute myocardial infarction and chronic ischemic heart disease.
Export Options
About this article
Cite this article as:
Donndorf Peter, Strauer Bodo-Eckhard, Haverich Axel and Steinhoff Gustav, Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease, Current Pharmaceutical Biotechnology 2013; 14 (1) . https://dx.doi.org/10.2174/1389201011314010004
DOI https://dx.doi.org/10.2174/1389201011314010004 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Adiposity and Alzheimers Disease
Current Alzheimer Research Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: Efficient Strategies for Signalling Pathway Mining (Guest Editors: Qingfeng Chen & Baoshan Chen)]
Current Protein & Peptide Science Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology Alkaptonuria, Ochronosis and Ochronotic Arthropathy in Mainland France and the Reunion Island. A Report of Clinical and Molecular Findings in 29 Patients
Current Rheumatology Reviews Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design Effects of Onion Extract on Endogenous Vascular H2S and Adrenomedulin in Rat Atherosclerosis
Current Pharmaceutical Biotechnology Postconditioning: A New Paradigm for Myocardial Protection?
Current Cardiology Reviews Editorial (Thematic Issues: New Developments in the Medicinal Chemistry of Some Azoles)
Current Topics in Medicinal Chemistry What’s Old is New Again – A Review of the Current Evidence of Colchicine in Cardiovascular Medicine
Current Cardiology Reviews Antimicrobial Stewardship in the Neonatal Intensive Care Unit: An Update
Current Pediatric Reviews Omega-3 Polyunsaturated Fatty Acids in Alzheimers Disease: Key Questions and Partial Answers
Current Alzheimer Research Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets